Mode of Action of RU 486
Authors:
- 1 January 1993
- journal article
- research article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 25 (1) , 61-64
Abstract
RU 486 is a 19-norsteroid which has a specific high affinity binding to the progesterone and glucocorticoid receptor. It is generally accepted that RU 486 acts as a pure progesterone antagonist almost without agonistic activity. RU 486 acts mainly directly on the target organ, such as the endometrium, but also to some extent indirectly through an effect on the pituitary gonadotrophin secretion. The effect of RU 486 during the menstrual cycle is dependent on time of treatment. Treatment before ovulation will result in a prolongation of the proliferative phase of the menstrual cycle, while treatment during the mid-and late luteal phase will invariably induce bleeding, often followed by a second bleeding episode at the expected time of menstruation. The only treatment period which does not influence the menstrual cycle is treatment immediately following ovulation. Treatment during the proliferative phase has no effect on endometrial morphology but inhibits follicular development and delays oestrogen and LH surge. Treatment on the first days following ovulation has no effect on ovarian steroid concentration, but will significantly delay endometrial development, cause a change in the concentration of oestrogen and progesterone receptor concentration, enzyme activity and production of substances thought to be progesterone dependent. The change in endometrial development is sufficient to prevent implantation. In mid-and late luteal phase, treatment with RU 486 will result in endometrial shedding in spite of normal progesterone levels. Post-ovulatory treatment with RU 486 will also significantly change uterine contractility. In early pregnancy, withdrawal of progesterone inhibition will result in uterine contractility and a significant increase in the sensitivity of the myometrium to prostaglandin. These effects are the scientific background for the combined treatment of RU 486 and prostaglandin for termination of early pregnancy. Clinical results indicate that the effect of RU 486 on the myometrial sensitivity to prostaglandins remains even during the second trimester of pregnancy. Treatment with RU 486 during pregnancy will also induce cervical ripening. The effect does not seem to be mediated through an increased endogeneous prostaglandin production, but inhibition of prostaglandin metabolism still remains a possible mode of action.Keywords
This publication has 18 references indexed in Scilit:
- Contraception with mifepristoneThe Lancet, 1991
- A multiparametric analysis of endometrial estrogen and progesterone receptors after the postovulatory administration of mifepristoneFertility and Sterility, 1991
- Regulation of non-pregnant human uterine contractilityContraception, 1990
- The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometriumHuman Reproduction, 1990
- Contragestion and Other Clinical Applications of RU 486, an Antiprogesterone at the ReceptorScience, 1989
- The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometriumHuman Reproduction, 1988
- Effects of an Antiprogesterone (RU486) on the Hypothalamic-Hypophyseal-Ovarian-Endometrial Axis During the Luteal Phase of the Menstrual Cycle*The Journal of Clinical Endocrinology & Metabolism, 1988
- Effects of the antiprogesterone RU 486 in normal womenAmerican Journal of Obstetrics and Gynecology, 1987
- Effect of the antiprogestin RU486 on progesterone production by cultured human granulosa cells: Inhibition of the ovarian 3B-Hydroxysteroid dehydrogenaseContraception, 1986
- Analogues of RU 486 for the Mapping of the Progestin Receptor: Synthetic and Structural Aspects1985